Columbia, SC-based Selah Genomics has formed a new clinical genomics center at the University of South Carolina’s Innovista research campus. The company is a clinical diagnostic specialist supporting healthcare providers and the pharmaceutical industry with molecular and genomic diagnostic services.
“Our new clinical genomics center at Innovista is already actively engaged with several pharmaceutical customers,” said Michael Bolick, Selah’s CEO. “Our team is now transferring our quality management practices from our other facilities to Columbia [SC] and we plan to file for CLIA registration for this new facility in the spring. These efforts also strengthen our ability to serve USC researchers and other clients worldwide.”
“With research and technology at the forefront of genomics, our partnership [with Selah] will help clinicians throughout South Carolina improve health outcomes for patients,” added Harris Pastides, president of the University of South Carolina.
Selah already is working with Frank Berger, Ph.D., at the university’s center for colon cancer research. “Selah brings the sequencing technology to researchers, who on their own have limited ability to mobilize such technology,” noted Dr. Berger.
According to Bolick, Selah Genomics growth has been supported by investments from Nexus Medical Partners and SCRA Technology Ventures’ Stage 2 Affiliate.
“We are at the beginning of a sea change in the practical application of genomics,” continued Bolick. “From here on in the rate of change will only accelerate.”